STOCK TITAN
  1. Home
  2. News
  3. LXRX

Lexicon Pharmaceuticals Inc - LXRX STOCK NEWS

Welcome to our dedicated news page for Lexicon Pharmaceuticals (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexicon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexicon Pharmaceuticals's position in the market.

News
Lexicon Pharmaceuticals to Host 2024 Investor Day
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host the Lexicon 2024 Investor Day on April 22, 2024, in New York City. The event will feature business and scientific updates from senior company executives and leading medical experts in areas such as Hypertrophic Cardiomyopathy, Type 1 Diabetes, and Diabetic Peripheral Neuropathic Pain. The webcast will be available on the Lexicon website for two weeks after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (LXRX) executives to participate in the 23rd Annual Needham Virtual Healthcare conference. Webcast available on Lexicon's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
conferences
-
News
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (LXRX) announces four data presentations on sotagliflozin at the ACC 73rd Annual Scientific Session. The presentations include reducing stroke events in patients with type 2 diabetes, CKD, and high CV risk, modulation of glucose transport and inflammatory proteins, inhibition of clotting potential, and a study on heart failure medication prescriptions. Sotagliflozin showed a 34% reduction in all-cause stroke risk, 32% reduction in ischemic stroke risk, and favorable actions in endothelial cells. The findings provide insights into sotagliflozin's mechanism of action and potential for cardiovascular protection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
clinical trial
News
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (LXRX) announced positive results from a post hoc analysis of the inTandem3 Phase 3 trial, showing that sotagliflozin improved glycemic control in type 1 diabetes and CKD patients. The treatment led to reduced A1C, body weight, and blood pressure with similar safety to the overall study group. The data was presented at ATTD 2024, indicating potential for sotagliflozin as an adjunct to insulin therapy for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.32%
Tags
none
-
News
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. reports progress in the commercial launch of INPEFA (sotagliflozin) with increasing demand and improved payer access. Key milestones include patient enrollment in a Phase 2b study of LX9211, preparations for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, and successful capital raise for growth initiatives. Financial results show revenue growth from INPEFA and increased R&D and SG&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.49%
Tags
earnings
-
News
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. announced a private investment in public equity financing, expecting to raise around $250 million. The company will sell approximately 2.3 million shares of Series A Convertible Preferred Stock at $108.50 per share, convertible into about 115.2 million common shares. Each preferred stock will convert into 50 common shares upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.49%
Tags
none
News
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. is preparing to resubmit its New Drug Application for sotagliflozin as an adjunct to insulin therapy for type 1 diabetes and chronic kidney disease, with an anticipated six-month regulatory review period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.49%
Tags
none
-
News
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting FDA approval for INPEFA® in heart failure and advancement of LX9211 for diabetic peripheral neuropathic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
News
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present at the 42nd Annual JPMorgan Healthcare Conference on January 11th, 2024. The company's CEO, Lonnel Coats, along with other key executives, will participate in the presentation, which will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
conferences
News
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has initiated the late-stage development program for AAK1 inhibitor LX9211, aiming to become the first new, non-opioid drug therapy for high-unmet need neuropathic pain in over 20 years. The PROGRESS study has enrolled the first patient, focusing on reducing Average Daily Pain Score (ADPS) in adult patients with type 1 or type 2 diabetes mellitus with moderate to severe Diabetic Peripheral Neuropathic Pain (DPNP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
clinical trial
Stock LXRX logo
Lexicon Pharmaceuticals Inc

Nasdaq:LXRX

LXRX Rankings

#3099 Ranked by Market Cap
#4623 Ranked by Stock Gains
N/A Ranked by Dividends

LXRX Stock Data

485.09M
100.03M
1.67%
82.16%
8.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
The Woodlands

About LXRX

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio